Pacer Advisors Inc. Grows Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Pacer Advisors Inc. grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 40.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,485 shares of the company’s stock after purchasing an additional 3,616 shares during the period. Pacer Advisors Inc.’s holdings in Medpace were worth $4,148,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in MEDP. Stone House Investment Management LLC acquired a new stake in Medpace in the third quarter worth about $33,000. Ashton Thomas Securities LLC purchased a new position in shares of Medpace in the 3rd quarter valued at approximately $37,000. Capital Performance Advisors LLP acquired a new stake in Medpace in the 3rd quarter worth approximately $46,000. True Wealth Design LLC grew its position in Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Medpace by 95.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company’s stock worth $93,000 after buying an additional 110 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on MEDP. Redburn Atlantic assumed coverage on shares of Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective on the stock. Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $350.04 on Friday. The stock has a market capitalization of $10.88 billion, a price-to-earnings ratio of 30.65, a PEG ratio of 1.77 and a beta of 1.36. The firm’s 50 day simple moving average is $342.11 and its 200-day simple moving average is $353.38. Medpace Holdings, Inc. has a 12 month low of $286.76 and a 12 month high of $459.77.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.